2,3,4′,5-Tetrahydroxystilbene-2-O-β-d-glucoside inhibits platelet-derived growth factor-induced proliferation of vascular smooth muscle cells by regulating the cell cycle

Clinical and Experimental Pharmacology and Physiology

Volumn 38, Issue 5, 2011, Pages 307-313

  Xu, Xiao Le ^a   Huang, Yan Juan ^a   Wang, Yu Qin ^a   Chen, Xiang Fan ^a   Zhang, Wei ^a  

^a NANTONG MEDICAL COLLEGE   (China)

Author keywords

2,3,4 ,5 tetrahydroxystilbene 2 O d glucoside; Cell cycle; Cell proliferation; Extracellular signal regulated kinase 1 2; Platelet derived growth factor; Vascular smooth muscle cells

Indexed keywords

2,3,4',5 TETRAHYDROXYSTILBENE 2 O BETA DEXTRO GLUCOSIDE; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN E; CYCLINE; MITOGEN ACTIVATED PROTEIN KINASE 1; PLANT EXTRACT; PLATELET DERIVED GROWTH FACTOR; PROTEIN P21; PROTEIN P27; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; MALE; NONHUMAN; POLYGONUM; PROTEIN EXPRESSION; RAT; RETINOBLASTOMA; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ANIMALS; CARDIOVASCULAR AGENTS; CELL CYCLE; CELL CYCLE PROTEINS; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION REGULATION; GLUCOSIDES; MALE; MODELS, BIOLOGICAL; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PLATELET-DERIVED GROWTH FACTOR; RATS; RATS, SPRAGUE-DAWLEY; STILBENES;

EID: 79955391862     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2011.05502.x     Document Type: Article

References (39)

1. Dzau VJ, Braun-Dullaeus RC, Sedding DG. Vascular proliferation and atherosclerosis: New perspectives and therapeutic strategies. Nat. Med. 2002; 8: 1249-56.
2. Sachinidis A, Locher R, Vetter W, Tatje D, Hoppe J. Different effects of platelet-derived growth factor isoforms on rat vascular smooth muscle cells. J. Biol. Chem. 1990; 265: 10.
3. Millette E, Rauch BH, Kenagy RD, Daum G, Clowes AW. Platelet-derived growth factor-BB transactivates the fibroblast growth factor receptor to induce proliferation in human smooth muscle cells. Trends Cardiovasc. Med. 2006; 16: 25-8.
4. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993; 362: 801-9.
5. Zhang H, Hannon GJ, Beach D. p21-containing cyclin kinases exist in both active and inactive states. Genes Dev. 1994; 8: 1750-8.
6. LaBaer J, Garrett MD, Stevenson LF et al. New functional activities for the p21 family of CDK inhibitors. Genes Dev. 1997; 11: 847-62.
7. Weiss RH, Joo A, Randour C. p21Waf1/Cip1 is an assembly factor required for platelet-derived growth factor-induced vascular smooth muscle cell proliferation. J. Biol. Chem. 2000; 275: 10.
8. Kavurma MM, Khachigian LM. Sp1 inhibits proliferation and induces apoptosis in vascular smooth muscle cells by repressing p21WAF1/Cip1 transcription and cyclin D1-Cdk4-p21WAF1/Cip1 complex formation. J. Biol. Chem. 2003; 278: 32537-43.
9. Zhang W, Wang CH, Li F, Zhu WZ. 2, 3, 4', 5-Tetrahydroxystilbene-2-O-β-d-glucoside suppresses matrix metalloproteinase expression and inflammation in atherosclerotic rats. Clin. Exp. Pharmacol. Physiol. 2008; 35: 310-6.
10. Zhang W, Xu XL, Wang YQ, Wang CH, Zhu WZ. Effects of 2, 3, 4', 5-tetrahydroxystilbene-2-O-β-d-glucoside on vascular endothelial dysfunction in atherogenic-diet rats. Planta Med. 2009; 75: 1209-14.
11. Cui HH, Tian Y, Ling SY. The effective mechanism of 2, 3, 4', 5-tetrahydroxystilbene-2-O-β-d-glucoside in anti-atherosclerosis. Prog. Mod. Biomed. 2009; 9: 3968-71. (in Chinese with an English abstract).
12. Liu QL, Xiao JH, Ma R, Ban Y, Wang JL. Effect of 2, 3, 4', 5-tetrahydroxystilbene-2-O-β-d-glucoside on lipoprotein oxidation and proliferation of coronary arterial smooth cells. J. Asian Nat. Prod. Res. 2007; 9: 689-97.
13. 2+in the inhibition by crocetin of angiotensin II-induced ERK1/2 activation in vascular smooth muscle cells. Eur. J. Pharmacol. 2007; 554: 85-91.
14. Uchida K, Sasahara M, Morigami N et al. Expression of platelet derived growth factor beta-chain in neointimal smooth muscle cells of balloon injured rabbit femoral arteries. Atherosclerosis 1996; 124: 9-23.
15. Bartek J, Bartkova J, Lukas J. The retinoblastoma protein pathway and the restriction point. Curr. Opin. Cell Biol. 1996; 8: 805-14.
16. Blagosklonny MV, Pardee AB. The restriction point of the cell cycle. Cell Cycle 2002; 1: 103-10.
17. Bloom J, Cross FR. Multiple levels of cyclin specificity in cell-cycle control. Nat. Rev. Mol. Cell Biol. 2007; 8: 149-60.
18. 1-phase progression. Genes Dev. 1999; 13: 1501-12.
19. Sherr CJ. G1 phase progression: Cycling on cue. Cell 1994; 79: 551-5.
20. Poznic M. Retinoblastoma protein: A central processing unit. J. Biosci. 2009; 34: 305-12.
21. Coqueret O. Linking cyclins to transcriptional control. Gene 2002; 299: 35-55.
22. Charron T, Nili N, Strauss BH. The cell cycle: A critical therapeutic target to prevent vascular proliferative disease. Can. J. Cardiol. 2006; 22(Suppl.): B41-55.
23. Genovese C, Trani D, Caputi M, Claudio PP. Cell cycle control and beyond. Emerging roles for the retinoblastoma gene family. Oncogene 2006; 25: 5201-9.
24. Lee JJ, Yu JY, Zhang WY et al. Inhibitory effect of fenofibrate on neointima hyperplasia via G(0)/G(1) arrest of cell proliferation. Eur. J. Pharmacol. 2011; 650: 342-9.
25. Naryzhny SN. Proliferating cell nuclear antigen: A proteomics view. Cell. Mol. Life Sci. 2008; 65: 3789-808.
26. Lee J, Kim SS. The function of p27 KIP1 during tumor development. Exp. Mol. Med. 2009; 41: 765-71.
27. Rao GN. Differential regulation of p27kip1 levels and CDK activities by hypertrophic and hyperplastic agents in vascular smooth muscle cells. Biochim. Biophys. Acta 1999; 1448: 525-32.
28. 1→S transition in vascular smooth muscle cells. J. Biol. Chem. 2000; 275: 22.
29. Tanner FC, Yang ZY, Duckers E, Gordon D, Nabel GJ, Nabel EG. Expression of cyclin-dependent kinase inhibitors in vascular disease. Circ. Res. 1998; 82: 396-403.
30. Tanner FC, Boehm M, Akyürek LM et al. Differential effects of the cyclin-dependent kinase inhibitors p27 (Kip1), 21 (Cip1), and p16 (Ink4) on vascular smooth muscle cell proliferation. Circulation 2000; 101: 2022-5.
31. Ghosh SS, Gehr TW, Ghosh S et al. PPARgamma ligand attenuates PDGF-induced mesangial cell proliferation: Role of MAP kinase. Kidney Int. 2003; 64: 52-62.
32. Kivinen L, Laiho M. Ras- and mitogen-activated protein kinase kinase-dependent and -independent pathways in p21Cip1/Waf1 induction by fibroblast growth factor-2, platelet-derived growth factor, and transforming growth factor-beta1. Cell Growth Differ. 1999; 10: 621-8.
33. Moon SK, Jung SY, Choi YH, Lee YC, Kim CH. Platelet-derived growth factor induces p21/WAF1 promoter in vascular smooth muscle cells via activation of an Sp1 site. FEBS Lett. 2003; 552: 130-4.
34. Lee B, Moon SK. Ras/ERK signaling pathway mediates activation of the p21WAF1 gene promoter in vascular smooth muscle cells by platelet-derived growth factor. Arch. Biochem. Biophys. 2005; 443: 113-9.
35. Andrés V. Unexpected proatherogenic properties of p21: Beyond cell cycle control? Circulation 2004; 110: 3749-52.
36. Meloche S, Pouysségur J. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene 2007; 26: 3227-39.
37. Castro C, Díez-Juan A, Cortés MJ, Andrés V. Distinct regulation of mitogen-activated protein kinases and p27Kip1 in smooth muscle cells from different vascular beds. A potential role in establishing regional phenotypic variance. J. Biol. Chem. 2003; 278: 4482-90.
38. Sears RC, Nevins JR. Signaling networks that link cell proliferation and cell fate. J. Biol. Chem. 2002; 277: 11.
39. Krishna M, Narang H. The complexity of mitogen-activated protein kinases (MAPKs) made simple. Cell. Mol. Life Sci. 2008; 65: 3525-44.